{
    "root": "2fc45a70-6807-1a6b-e063-6294a90abced",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Buprenorphine and Naloxone",
    "value": "20250307",
    "ingredients": [
        {
            "name": "ACESULFAME POTASSIUM",
            "code": "23OV73Q5G9",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_83501"
        },
        {
            "name": "BUTYLATED HYDROXYANISOLE",
            "code": "REK4960K2U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_76359"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30769"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "MALTITOL",
            "code": "D65DG142WK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68428"
        },
        {
            "name": "POLYETHYLENE OXIDE 1000000",
            "code": "HZ58M6D839",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25741"
        },
        {
            "name": "POLYETHYLENE OXIDE 2000000",
            "code": "5K3991GVWI",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25741"
        },
        {
            "name": "POLYETHYLENE OXIDE 900000",
            "code": "16P9295IIL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25741"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14478"
        },
        {
            "name": "SODIUM CITRATE, UNSPECIFIED FORM",
            "code": "1Q73Q2JULR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53258"
        },
        {
            "name": "SODIUM METABISULFITE",
            "code": "4VON5FNS3C",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15842"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "BUPRENORPHINE HYDROCHLORIDE",
            "code": "56W8MW3EN1",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_652822"
        },
        {
            "name": "NALOXONE HYDROCHLORIDE",
            "code": "F850569PQR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31892"
        }
    ],
    "indications": {
        "text": "buprenorphine naloxone sublingual film indicated treatment opioid dependence . buprenorphine naloxone sublingual film used part complete treatment plan includes counseling psychosocial support .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "administer buprenorphine naloxone sublingual film single daily dose . ( 2.1 ) strongly consider prescribing naloxone time buprenorphine naloxone sublingual film initiated renewed patients treated opioid disorder potential relapse , putting risk opioid overdose . ( 2.2 ) avoid precipitating withdrawal , induction buprenorphine naloxone sublingual film undertaken objective clear signs withdrawal evident buprenorphine naloxone sublingual film administered divided doses used initial treatment . ( 2.3 ) patients dependent short-acting opioid products opioid withdrawal ; day 1 , administer 8 mg/2 mg buprenorphine naloxone sublingual film ( divided doses ) . day 2 , administer 16 mg/4 mg buprenorphine naloxone sublingual film single dose . ( 2.3 ) patients dependent methadone long-acting opioid products , induction onto sublingual buprenorphine monotherapy recommended days 1 2 treatment . ( 2.3 ) maintenance treatment , target buprenorphine naloxone sublingual film usually 16 mg/4 mg single daily dose . ( 2.4 ) sublingual : place one film tongue , close base left right side , allow completely dissolve . buccal : place one film inside left right cheek allow completely dissolve . ( 2.5 ) buprenorphine naloxone sublingual film must administered whole . cut , chew , swallow buprenorphine naloxone sublingual film ( 2.5 ) discontinuing treatment , gradually taper avoid signs symptoms withdrawal . ( 2.8 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "buprenorphine 2 mg naloxone 0.5 mg sublingual film supplied rectangular orange film , contains whitish particulates dispersed throughout film areas lighter color , observed aluminized side pouchstock material . film imprinted \u201c 2 \u201d blue ink ( \u201c 2 \u201d may appear green color ) . pouch tear-notch . ndc 50742-397-30 - 30 films per carton buprenorphine 4 mg naloxone 1 mg sublingual film supplied rectangular orange film , contains whitish particulates dispersed throughout film areas lighter color , observed aluminized side pouchstock material . film imprinted \u201c 4 \u201d blue ink ( \u201c 4 \u201d may appear green color ) , pouch tear-notch . ndc 50742-398-30 - 30 films per carton buprenorphine 8 mg naloxone 2 mg sublingual film supplied rectangular orange film , contains whitish particulates dispersed throughout film areas lighter color , observed aluminized side pouchstock material . film imprinted \u201c 8 \u201d blue ink ( \u201c 8 \u201d may appear green color ) , pouch tear-notch . ndc 50742-364-30 - 30 films per carton buprenorphine 12 mg naloxone 3 mg sublingual film supplied rectangular orange film , contains whitish particulates dispersed throughout film areas lighter color , observed aluminized side pouchstock material . film imprinted \u201c 12 \u201d blue ink ( \u201c 12 \u201d may appear green color ) , pouch tear-notch . ndc 50742-365-30 - 30 films per carton store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) , excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . store buprenorphine naloxone sublingual film securely dispose properly [ patient counseling information ( 17 ) ] .",
    "adverseReactions": "buprenorphine naloxone sublingual film contraindicated patients history hypersensitivity buprenorphine naloxone serious , including anaphylactic shock , reported [ ( 5.9 ) ] .",
    "indications_original": "Buprenorphine and naloxone sublingual film is indicated for treatment of opioid dependence. Buprenorphine and naloxone sublingual film should be used as part of a complete treatment plan that includes counseling and psychosocial support.",
    "contraindications_original": "Administer buprenorphine and naloxone sublingual film as a single daily dose.\u00a0( 2.1 ) Strongly consider prescribing naloxone at the time buprenorphine and naloxone sublingual film is initiated or renewed because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose. ( 2.2 ) To avoid precipitating withdrawal, induction with buprenorphine and naloxone\u00a0sublingual\u00a0film\u00a0should\u00a0be\u00a0undertaken\u00a0when\u00a0objective\u00a0and\u00a0clear signs of withdrawal are evident and buprenorphine and naloxone sublingual film should be administered in divided doses when used as initial treatment. ( 2.3 ) For\u00a0patients dependent\u00a0on\u00a0short-acting\u00a0opioid\u00a0products\u00a0who\u00a0are\u00a0in\u00a0opioid withdrawal; on Day 1, administer up to 8 mg/2 mg buprenorphine and naloxone sublingual film (in divided doses). On Day 2, administer up to 16 mg/4 mg of buprenorphine and naloxone sublingual film as a single dose. ( 2.3 ) For patients dependent on methadone or long-acting opioid products, induction\u00a0onto\u00a0sublingual\u00a0buprenorphine\u00a0monotherapy\u00a0is\u00a0recommended on Days 1 and 2 of treatment.\u00a0( 2.3 ) For maintenance treatment, the target dosage of buprenorphine and naloxone\u00a0sublingual\u00a0film\u00a0is\u00a0usually 16\u00a0mg/4\u00a0mg\u00a0as\u00a0a\u00a0single\u00a0daily dose.\u00a0( 2.4 ) Sublingual Administration: Place one film under the tongue, close to\u00a0the base on the left or right side, and allow to completely\u00a0dissolve. Buccal Administration: Place one film on the inside of the left or right cheek and allow to completely dissolve. ( 2.5 ) Buprenorphine and naloxone sublingual film must be administered whole. Do not cut, chew, or swallow buprenorphine and naloxone sublingual film\u00a0( 2.5 ) When discontinuing treatment, gradually taper to avoid signs\u00a0and symptoms of withdrawal. ( 2.8 )",
    "warningsAndPrecautions_original": "Buprenorphine 2 mg and naloxone 0.5 mg sublingual film is supplied as a rectangular orange film, which contains whitish particulates dispersed throughout the film and areas of lighter color, when observed against the aluminized side of the pouchstock material. The film is imprinted with \u201c2\u201d in blue ink (\u201c2\u201d may appear to be green in color). The pouch has a tear-notch.\n                  \n                     NDC 50742-397-30 - 30 films per carton\n                  \n                  Buprenorphine 4 mg and naloxone 1 mg sublingual film is supplied as a rectangular orange film, which contains whitish particulates dispersed throughout the film and areas of lighter color, when observed against the aluminized side of the pouchstock material. The film is imprinted with \u201c4\u201d in blue ink (\u201c4\u201d may appear to be green in color), The pouch has a tear-notch.\n                  \n                     NDC 50742-398-30 - 30 films per carton\n                  \n                  Buprenorphine 8 mg and naloxone 2 mg sublingual film is supplied as a rectangular orange film, which contains whitish particulates dispersed throughout the film and areas of lighter color, when observed against the aluminized side of the pouchstock material. The film is imprinted with \u201c8\u201d in blue ink (\u201c8\u201d may appear to be green in color), The pouch has a tear-notch.\n                  \n                     NDC 50742-364-30 - 30 films per carton\n                  \n                  Buprenorphine 12 mg and naloxone 3 mg sublingual film is supplied as a rectangular orange film, which contains whitish particulates dispersed throughout the film and areas of lighter color, when observed against the aluminized side of the pouchstock material. The film is imprinted with \u201c12\u201d in blue ink (\u201c12\u201d may appear to be green in color), The pouch has a tear-notch.\n                  \n                     NDC 50742-365-30 - 30 films per carton\n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F), excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].\n                  Store buprenorphine and naloxone sublingual film securely and dispose of properly\n \n  [see Patient Counseling Information (\n  \n   17)] .",
    "adverseReactions_original": "Buprenorphine and naloxone sublingual film is contraindicated in patients with a history of hypersensitivity to buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported\n \n  [see Warnings and Precautions (\n  \n   5.9)].",
    "drug": [
        {
            "name": "Buprenorphine and Naloxone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3216"
        }
    ]
}